The effects of hepatitis C virus core protein on the expression of miR-122 in vitro

Virology Journal

Volumn 10, Issue , 2013, Pages

  Li, Sujuan ^a   Xing, Xiaokang ^a   Yang, Qiao ^a   Xu, Hangdi ^a   He, Jiliang ^b   Chen, Zhi ^a   Zhu, Haihong ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CORE PROTEIN; MICRORNA 122;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; NONHUMAN; PLASMID; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; VIRUS CELL INTERACTION;

HEPATITIS C VIRUS;

EID: 84875340222     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-98     Document Type: Article

References (30)

1. Hepatitis C virus infection. Lauer GM, Walker BD, N Engl J Med 2001 345 1 41 52 10.1056/NEJM200107053450107 11439948
2. Immunology of hepatitis B virus and hepatitis C virus infection. Rehermann B, Nascimbeni M, Nat Rev Immunol 2005 5 3 215 229 10.1038/nri1573 15738952
3. Peginterferon alfa-2a plus ribavirin for chronic hepatitis c virus infection. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J, N Engl J Med 2002 347 13 975 982 10.1056/NEJMoa020047 12324553
4. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM, PEGASYS International Study Group, Ann Intern Med 2004 140 5 346 355 14996676
5. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK, Lancet 2001 358 9286 958 965 10.1016/S0140-6736(01)06102-5 11583749
6. Boceprevir for untreated chronic HCV genotype 1 infection. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP, SPRINT-2 Investigators, N Engl J Med 2011 364 13 1195 1206 10.1056/NEJMoa1010494 21449783
7. Boceprevir for previously treated chronic HCV genotype 1 infection. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R, HCV RESPOND-2 Investigators, N Engl J Med 2011 364 13 1207 1217 10.1056/ NEJMoa1009482 21449784
8. Telaprevir for previously untreated chronic hepatitis C virus infetion. Jacobson IM, McHutchison JG, Dscheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzeto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, ADVANCE Study Team, N Engl J Med 2011 364 25 2405 2416 10.1056/NEJMoa1012912 21696307
9. Telaprevir for retreatment of HCV infetion. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Hrban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, Van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M, REALIZE Study Team, N Engl J Med 2011 364 25 2417 2428 10.1056/NEJMoa1013086 21696308
10. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Inhof I, Simmonds P, Hepatology 2011 53 4 1090 1099 10.1002/hep.24172 21480315
11. Chronic hepatitis C virus infection. Flamm SL, JAMA 2003 289 18 2413 2417 10.1001/jama.289.18.2413 12746366
12. Expression of hepatitis C virus core protein inhibits interferon-induced nuclear import of STATs. Melen K, Fagerlund R, Nyqvist M, Keskinen P, Julkunen I, J Med Virol 2004 73 4 536 547 10.1002/jmv.20123 15221897
13. Effects of the hepatitis C virus core protein on innate cellular defense pathways. Miller K, McArdle S, Gale MJ Jr, Geller DA, Tenoever B, Hiscott J, Gretch DR, Polyak SJ, J Interferon Cytokine Res 2004 24 7 391 402 10.1089/1079990041535647 15296650
14. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM, Science 1999 285 5424 107 110 10.1126/science.285.5424.107 10390359
15. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, Ray SC, Gale M Jr, Lemon SM, Proc Natl Acad Sci USA 2005 102 8 2992 2997 10.1073/pnas.0408824102 15710891
16. Hepatitis C virus protease NS3/4A mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ, Proc Natl Acad Sci USA 2005 102 49 17717 17722 10.1073/pnas.0508531102 16301520
17. The NS5A protein of hepatitis C virus partially inhibits the antiviral activity of interferon. Song J, Fujii M, Wang F, Itoh M, Hotta H, J Gen Virol 1999 80 Pt 4 879 886 10211956
18. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA, Xu C, Mason WS, Moloshok T, Bort R, Zaret KS, Taylor JM, RNA Biol 2004 1 2 106 113 10.4161/rna.1.2.1066 17179747
19. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P, Science 2005 309 5740 1577 1581 10.1126/science.1113329 16141076
20. microRNA-122 stimulates translation of hepatitis C virus RNA. Henke JI, Goergen D, Zheng J, Song Y, Schttler CG, Fehr C, Jnemann C, Niepmann M, EMBO J 2008 27 24 3300 3310 10.1038/emboj.2008.244 19020517
21. Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Shan Y, Zheng J, Lambrecht RW, Bonkovsky HL, Gastroenterology 2007 133 4 1166 1174 10.1053/j.gastro.2007.08.002 17919492
22. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L, PLoS One 2011 6 8 23937 10.1371/journal.pone.0023937 21886843
23. Cellular cofactors affecting hepatitis C virus infection and replication. Randall G, Panis M, Cooper JD, Tellinghuisen TL, Sukhodolets KE, Pfeffer S, Landthaler M, Landgraf P, Kan S, Lindenbach BD, Chien M, Weir DB, Russo JJ, Ju J, Brownstein MJ, Sheridan R, Sander C, Zavolan M, Tuschl T, Rice CM, Proc Natl Acad Sci USA 2007 104 31 12884 12889 10.1073/pnas.0704894104 17616579
24. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Marquez RT, Bandyopadhyay S, Wendlandt EB, Keck K, Hoffer BA, Icardi MS, Christensen RN, Schmidt WN, McCaffrey AP, Lab Invest 2010 90 12 1727 1736 10.1038/labinvest. 2010.126 20625373
25. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W, Nat Med 2009 15 1 31 33 10.1038/nm.1902 19122656
26. Clinical significance and potential of hepatic microRNA-122 expression in hepatitis C. Morita K, Taketomi A, Shirabe K, Umeda K, Kayashima H, Ninomiya M, Uchiyama H, Soejima Y, Maehara Y, Liver Int 2011 31 4 474 484 10.1111/j.1478-3231.2010.02433.x 21199296
27. Replicative homeostasis: a mechanism of viral persistence. Sallie R, Med Hypotheses 2004 63 3 515 523 10.1016/j.mehy.2004.02.050 15288380
28. Replicative homeostasis: a fundamental mechanism mediating selective viral replication and escape mutation. Sallie R, Virol J 2005 2 10 10.1186/1743-422X-2-10 15707489
29. Replicative homeostasis II: influence of polymerase fidelity on RNA virus quasispecies biology: implications for immune recognition, viral autoimmunity and other «virus receptor» diseases. Sallie R, Virol J 2005 2 70 10.1186/1743-422X-2-70 16115320
30. Replicative homeostasis III: implications for antiviral therapy and mechanisms of response and non-response. Sallie R, Virol J 2007 4 29 10.1186/1743-422X-4-29 17355620